The Hormonal Profile of Norethindrone Acetate: Rationale for Add-Back Therapy With Gonadotropin-Releasing Hormone Agonists in Women With Endometriosis
@article{Chwalisz2012TheHP, title={The Hormonal Profile of Norethindrone Acetate: Rationale for Add-Back Therapy With Gonadotropin-Releasing Hormone Agonists in Women With Endometriosis}, author={K. Chwalisz and E. Surrey and F. Stanczyk}, journal={Reproductive Sciences}, year={2012}, volume={19}, pages={563 - 571} }
Gonadotropin-releasing hormone agonists (GnRHa) are an effective treatment of endometriosis-associated pelvic pain. The use of hormonal add-back therapy can alleviate the hypoestrogenic symptoms associated with GnRHa therapy, while preserving therapeutic efficacy. Norethindrone acetate (NETA) is a unique progestin that has both estrogenic and androgenic properties and is effective as an add-back regimen without estrogen supplementation. Through its estrogenic activity, NETA exerts beneficial… CONTINUE READING
33 Citations
Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis
- Medicine
- Expert opinion on drug metabolism & toxicology
- 2020
- 1
Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone
- Medicine
- BioMed research international
- 2015
- 10
- PDF
Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
- Medicine
- Journal of managed care & specialty pharmacy
- 2016
- 5
Estrogen-progestins and progestins for the management of endometriosis.
- Medicine
- Fertility and sterility
- 2016
- 82
Advances in pharmacotherapy for treating endometriosis
- Medicine
- Expert opinion on pharmacotherapy
- 2015
- 22
Elagolix, a Novel, Orally Bioavailable GnRH Antagonist under Investigation for the Treatment of Endometriosis-Related Pain
- Medicine
- Women's health
- 2015
- 26
Oral and depot progestin therapy for endometriosis: towards a personalized medicine
- Medicine
- Expert opinion on pharmacotherapy
- 2017
- 8
- PDF
Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture.
- Medicine
- Fertility and sterility
- 2019
Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis
- Medicine
- Expert opinion on drug metabolism & toxicology
- 2018
- 23
- PDF
Medical treatment of endometriosis-related pain.
- Medicine
- Best practice & research. Clinical obstetrics & gynaecology
- 2018
- 36
- PDF
References
SHOWING 1-10 OF 91 REFERENCES
Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
- Medicine
- Current opinion in obstetrics & gynecology
- 2010
- 44
Add-back therapy use and its impact on LA persistence in patients with endometriosis
- Medicine
- Current medical research and opinion
- 2010
- 19
Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group.
- Medicine
- Fertility and sterility
- 1999
- 73
Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia.
- Medicine
- Maturitas
- 2004
- 24
Hormone treatment of endometriosis: the estrogen threshold hypothesis.
- Medicine
- American journal of obstetrics and gynecology
- 1992
- 127
Gonadotropin-releasing hormone agonists for endometriosis.
- Medicine
- The New England journal of medicine
- 2008
- 21
Leuprolide Acetate Depot and Hormonal Add‐Back in Endometriosis: A 12‐Month Study
- Medicine
- Obstetrics and gynecology
- 1998
- 138
One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial.
- Medicine
- Human reproduction
- 2004
- 42
- PDF
Advances in the management of endometriosis: an update for clinicians.
- Medicine
- Human reproduction update
- 2006
- 215
- PDF